Meeting
2021 ASCO Annual Meeting
Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.
Authors
Chao Lyu
Thoracic Surgery II, Peking University Cancer Hospital, Beijing, China
Chao Lyu , Rui Wang , Shaolei Li , Shi Yan , Yuzhao Wang , Jinfeng Chen , Liang Wang , Yinan Liu , Zhanlin Guo , Jia Wang , Yuquan Pei , Lei Yu , Nan Wu , Jun Chen , Yanheng Liu , Shanqing Li , Bing Han , Lieming Ding , Li Mao , Yue Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT01929200
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8521)
DOI
10.1200/JCO.2021.39.15_suppl.8521
Abstract #
8521
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).
First Author: Jianxing He
Poster
2023 ASCO Annual Meeting
Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.
First Author: Carlos Pedraz
Poster
2019 ASCO Annual Meeting
The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung cancer.
First Author: Peng Xie
Poster
2018 ASCO Annual Meeting
An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).
First Author: Myung-Ju Ahn